{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:50:44Z","timestamp":1790567444544,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The tumor immune microenvironment (TIME) is a critical determinant of prognosis in acute myeloid leukemia (AML). This study aimed to develop a prognostic model based on immune-related hub differentially expressed genes (hub-DEGs) to refine risk stratification and identify therapeutic targets. Transcriptomic and clinical data from 149 TCGA-AML patients were analyzed using ESTIMATE and xCell algorithms to infer immune scores. Differentially expressed genes (DEGs) between high\/low immune score groups were identified, followed by functional enrichment, protein-protein interaction (PPI) network analysis for selecting the hub-DEGs with the highest degree scores, and univariate Cox regression to pinpoint prognostic genes. External validation was performed on 562 GEO-AML patients. The final genes were selected by intersecting the prognostic DEGs and hub-DEGs. Next the immune prognostic model (IPM) was created using these genes. xCell and CIBERSORT algorithm were used to assess the correlation of IPM and different immune cells. Finally, Experimental validation of key genes (CD163, MRC1) was conducted via RT-PCR in 40 AML and 10 control samples. Immune scores correlated with FAB classification (ESTIMATE: <jats:italic>p-value<\/jats:italic>\u2009=\u20091.4e\u2009\u2212\u20098; xCell: <jats:italic>p-value<\/jats:italic>\u2009=\u20093.7e\u2009\u2212\u20099) and overall survival (ESTIMATE: v\u2009=\u20090.041). Analysis identified 680 immune-related DEGs enriched in immune response pathways. Intersection of prognostic DEGs (<jats:italic>n<\/jats:italic>\u2009=\u200934) and hub-DEGs (<jats:italic>n<\/jats:italic>\u2009=\u200930) yielded four genes (CD163, IL10, MRC1, FCGR2B). A risk score model stratified patients into high\/low-risk groups with divergent survival (<jats:italic>p-value<\/jats:italic>\u2009=\u20090.00072). ROC analysis demonstrated predictive accuracy (AUC: 63.38\u201368.5% for 1\u20135-year survival). TIME analysis revealed associations between high-risk scores and immunosuppressive cell subsets, including Tregs and M2 macrophages. RT-qPCR confirmed elevated CD163 in AML (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while MRC1 showed no differential expression. This study establishes a TIME-centric prognostic model with clinical utility for risk stratification and therapeutic targeting in AML. Prospective validation and integration of advanced genomic technologies are warranted to refine its translational applicability.<\/jats:p>","DOI":"10.1038\/s41598-025-03557-9","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:40:00Z","timestamp":1752849600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Constructing a tumor immune microenvironment-driven prognostic model in acute myeloid leukemia using bioinformatics and validation data"],"prefix":"10.1038","volume":"15","author":[{"given":"Amir Abbas","family":"Navidinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bentol Hoda Kuhestani","family":"Dehaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Khayami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najibe","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi Allahbakhshian","family":"Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"10147","key":"3557_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet. 392 (10147), 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"3557_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-019-00443-9","volume":"24","author":"F Yang","year":"2020","unstructured":"Yang, F., Anekpuritanang, T. & Press, R. D. Clinical utility of next-generation sequencing in acute myeloid leukemia. Mol. Diagn. Ther. 24, 1\u201313 (2020).","journal-title":"Mol. Diagn. Ther."},{"issue":"5","key":"3557_CR3","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1002\/cam4.5408","volume":"12","author":"A Calleja","year":"2023","unstructured":"Calleja, A. et al. Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia. Cancer Med. 12 (5), 5656\u20135660 (2023).","journal-title":"Cancer Med."},{"issue":"1","key":"3557_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.24246","volume":"91","author":"H Kantarjian","year":"2016","unstructured":"Kantarjian, H. Acute myeloid leukemia\u2013major progress over four decades and glimpses into the future. Am. J. Hematol. 91 (1), 131\u2013145 (2016).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"3557_CR5","first-page":"319","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol, F., Schlenk, R. F., Heuser, M. & Ganser, A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. J. Am. Soc. Hematol. 126 (3), 319\u2013327 (2015).","journal-title":"J. Am. Soc. Hematol."},{"issue":"3","key":"3557_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 98 (3), 502\u2013526 (2023).","journal-title":"Am. J. Hematol."},{"key":"3557_CR7","doi-asserted-by":"crossref","unstructured":"Wang, Q. et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. (2023).","DOI":"10.1002\/cam4.5698"},{"issue":"11","key":"3557_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13 (11), 759\u2013771 (2013).","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"3557_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17 (9), 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"3557_CR10","doi-asserted-by":"publisher","first-page":"692800","DOI":"10.3389\/fcell.2021.692800","volume":"9","author":"KE Miari","year":"2021","unstructured":"Miari, K. E., Guzman, M. L., Wheadon, H. & Williams, M. T. Macrophages in acute myeloid leukaemia: significant players in therapy resistance and patient outcomes. Front. Cell. Dev. Biol. 9, 692800 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"10","key":"3557_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","volume":"101","author":"YS Al-Matary","year":"2016","unstructured":"Al-Matary, Y. S. et al. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner. Haematologica. 101 (10), 1216 (2016).","journal-title":"Haematologica"},{"issue":"7","key":"3557_CR12","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"A Curti","year":"2007","unstructured":"Curti, A. et al. Modulation of Tryptophan catabolism by human leukemic cells results in the conversion of CD25\u2009\u2013\u2009into CD25\u2009+\u2009T regulatory cells. Blood. 109 (7), 2871\u20132877 (2007).","journal-title":"Blood"},{"issue":"1","key":"3557_CR13","doi-asserted-by":"publisher","first-page":"12892","DOI":"10.1038\/s41598-017-12940-0","volume":"7","author":"A Mangaonkar","year":"2017","unstructured":"Mangaonkar, A. et al. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2, 3 dioxygenase expression. Sci. Rep. 7 (1), 12892 (2017).","journal-title":"Sci. Rep."},{"issue":"5","key":"3557_CR14","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","volume":"56","author":"K Fukuno","year":"2015","unstructured":"Fukuno, K. et al. Expression of indoleamine 2, 3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk. Lymphoma. 56 (5), 1398\u20131405 (2015).","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"3557_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18 (1), 1\u201314 (2017).","journal-title":"Genome Biol."},{"issue":"1","key":"3557_CR16","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4 (1), 2612 (2013).","journal-title":"Nat. Commun."},{"key":"3557_CR17","doi-asserted-by":"crossref","unstructured":"Deng, Z. et al. Mining TCGA database for tumor microenvironment-related genes of prognostic value in hepatocellular carcinoma. BioMed Res. Int. 2019. (2019).","DOI":"10.1155\/2019\/2408348"},{"issue":"4","key":"3557_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","volume":"10","author":"D Jia","year":"2018","unstructured":"Jia, D. et al. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY). 10 (4), 592 (2018).","journal-title":"Aging (Albany NY)"},{"key":"3557_CR19","doi-asserted-by":"publisher","first-page":"e27861","DOI":"10.7554\/eLife.27861","volume":"6","author":"N Shah","year":"2017","unstructured":"Shah, N. et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife 6, e27861 (2017).","journal-title":"Elife"},{"issue":"3","key":"3557_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/bjc.2017.208","volume":"117","author":"MH Alonso","year":"2017","unstructured":"Alonso, M. H. et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br. J. Cancer. 117 (3), 421\u2013431 (2017).","journal-title":"Br. J. Cancer"},{"key":"3557_CR21","doi-asserted-by":"crossref","unstructured":"Priedigkeit, N. et al. Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight. 2(17). (2017).","DOI":"10.1172\/jci.insight.95703"},{"issue":"19","key":"3557_CR22","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1111\/jcmm.15595","volume":"24","author":"Q Lan","year":"2020","unstructured":"Lan, Q., Wang, P., Tian, S. & Dong, W. Mining TCGA database for genes of prognostic value in gastric cancer microenvironment. J. Cell. Mol. Med. 24 (19), 11120\u201311132 (2020).","journal-title":"J. Cell. Mol. Med."},{"issue":"4","key":"3557_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013 \u2206\u2206CT method. Methods. 25 (4), 402\u2013408 (2001).","journal-title":"Methods"},{"issue":"6","key":"3557_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3390\/biomedicines10061410","volume":"10","author":"C Hino","year":"2022","unstructured":"Hino, C. et al. Targeting the tumor microenvironment in acute myeloid leukemia: the future of immunotherapy and natural products. Biomedicines. 10 (6), 1410 (2022).","journal-title":"Biomedicines"},{"issue":"11","key":"3557_CR25","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1038\/s41375-021-01377-0","volume":"35","author":"F Hu","year":"2021","unstructured":"Hu, F. et al. Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. Leukemia. 35 (11), 3073\u20133077 (2021).","journal-title":"Leukemia"},{"issue":"530","key":"3557_CR26","doi-asserted-by":"publisher","first-page":"eaax6337","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes, J. M. et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12 (530), eaax6337 (2020).","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"3557_CR27","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1021\/acs.molpharmaceut.0c00226","volume":"17","author":"A Lepland","year":"2020","unstructured":"Lepland, A. et al. Targeting pro-tumoral macrophages in early primary and metastatic breast tumors with the CD206-binding mUNO peptide. Mol. Pharm. 17 (7), 2518\u20132531 (2020).","journal-title":"Mol. Pharm."},{"issue":"13","key":"3557_CR28","first-page":"1533","volume":"140","author":"MH Kramer","year":"2022","unstructured":"Kramer, M. H. et al. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. Blood J. Am. Soc. Hematol. 140 (13), 1533\u20131548 (2022).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"3557_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.21037\/tcr-20-2712","volume":"10","author":"D Cai","year":"2021","unstructured":"Cai, D. et al. Identification of six hub genes and analysis of their correlation with drug sensitivity in acute myeloid leukemia through bioinformatics. Transl. Cancer Res. 10 (1), 126 (2021).","journal-title":"Transl. Cancer Res."},{"key":"3557_CR30","doi-asserted-by":"publisher","first-page":"1063227","DOI":"10.3389\/fgene.2023.1063227","volume":"14","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. High-expression of the innate-immune related gene UNC93B1 predicts inferior outcomes in acute myeloid leukemia. Front. Genet. 14, 1063227 (2023).","journal-title":"Front. Genet."},{"key":"3557_CR31","doi-asserted-by":"publisher","first-page":"1178337","DOI":"10.3389\/fimmu.2023.1178337","volume":"14","author":"P Chaintreuil","year":"2023","unstructured":"Chaintreuil, P., Kerreneur, E. & Jacquel, A. The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. Front. Immunol. 14, 1178337 (2023).","journal-title":"Front. Immunol."},{"issue":"1","key":"3557_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 12 (1), 134\u2013153 (2022).","journal-title":"Cancer Discov."},{"issue":"16","key":"3557_CR33","first-page":"1762","volume":"133","author":"ED Hsi","year":"2019","unstructured":"Hsi, E. D. et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in hodgkin lymphoma: a SWOG S0816 correlative study. Blood J. Am. Soc. Hematol. 133 (16), 1762\u20131765 (2019).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7","key":"3557_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/neuonc\/not028","volume":"15","author":"H Kanno","year":"2013","unstructured":"Kanno, H. et al. Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro-oncology. 15 (7), 853\u2013864 (2013).","journal-title":"Neuro-oncology"},{"issue":"5","key":"3557_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ejh.13371","volume":"104","author":"SL Kvorning","year":"2020","unstructured":"Kvorning, S. L. et al. Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma. Eur. J. Haematol. 104 (5), 409\u2013419 (2020).","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"3557_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.55133\/eji.300308","volume":"30","author":"HM Ragab","year":"2023","unstructured":"Ragab, H. M. et al. Soluble CD163 impact as a prognostic biomarker in chronic lymphocytic leukemia. Egypt. J. Immunol. 30 (3), 74\u201381 (2023).","journal-title":"Egypt. J. Immunol."},{"key":"3557_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei, C. et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal Circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer. 18, 1\u201323 (2019).","journal-title":"Mol. Cancer"},{"key":"3557_CR38","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00262-019-02408-7","volume":"68","author":"H Yan","year":"2019","unstructured":"Yan, H. et al. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. Cancer Immunol. Immunother. 68, 1971\u20131978 (2019).","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"3557_CR39","doi-asserted-by":"publisher","first-page":"1683347","DOI":"10.1080\/2162402X.2019.1683347","volume":"9","author":"Z-J Xu","year":"2020","unstructured":"Xu, Z-J. et al. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology 9 (1), 1683347 (2020).","journal-title":"Oncoimmunology"},{"issue":"4","key":"3557_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/BS9.0000000000000092","volume":"3","author":"H Shapoorian","year":"2021","unstructured":"Shapoorian, H., Zalpoor, H. & Ganjalikhani-Hakemi, M. The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia. Blood Sci. 3 (4), 132\u2013135 (2021).","journal-title":"Blood Sci."},{"issue":"1","key":"3557_CR41","doi-asserted-by":"publisher","first-page":"40707","DOI":"10.1038\/srep40707","volume":"7","author":"MR Lopes","year":"2017","unstructured":"Lopes, M. R. et al. De Novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Sci. Rep. 7 (1), 40707 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"3557_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41375-021-01375-2","volume":"36","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. Leukemia 36 (2), 403\u2013415 (2022).","journal-title":"Leukemia"},{"issue":"3","key":"3557_CR43","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2013.12.041","volume":"156","author":"CP Pallasch","year":"2014","unstructured":"Pallasch, C. P. et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156 (3), 590\u2013602 (2014).","journal-title":"Cell"},{"issue":"15","key":"3557_CR44","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/bloodadvances.2021004770","volume":"5","author":"M Nowicka","year":"2021","unstructured":"Nowicka, M. et al. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Adv. 5 (15), 2945\u20132957 (2021).","journal-title":"Blood Adv."},{"key":"3557_CR45","doi-asserted-by":"crossref","unstructured":"Simpson, A. P. et al. Fc\u03b3RIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell. Rep. 40(3). (2022).","DOI":"10.1016\/j.celrep.2022.111099"},{"issue":"5","key":"3557_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nri2762","volume":"10","author":"KG Smith","year":"2010","unstructured":"Smith, K. G. & Clatworthy, M. R. Fc\u03b3RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10 (5), 328\u2013343 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"3557_CR47","doi-asserted-by":"crossref","unstructured":"Bournazos, S., Wang, T. T. & Ravetch, J. V. The role and function of Fc\u03b3 receptors on myeloid cells. Myeloid Cells Health Dis. Synth. 405\u2013427 (2017).","DOI":"10.1128\/9781555819194.ch22"},{"key":"3557_CR48","doi-asserted-by":"publisher","first-page":"440068","DOI":"10.3389\/fimmu.2019.00481","volume":"10","author":"I Teige","year":"2019","unstructured":"Teige, I., M\u00e5rtensson, L. & Frend\u00e9us, B. L. Targeting the antibody checkpoints to enhance cancer immunotherapy\u2013focus on Fc\u03b3RIIB. Front. Immunol. 10, 440068 (2019).","journal-title":"Front. Immunol."},{"issue":"1","key":"3557_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-022-02294-5","volume":"41","author":"K Hussain","year":"2022","unstructured":"Hussain, K. et al. HIF activation enhances Fc\u03b3RIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. J. Exp. Clin. Cancer Res. 41 (1), 131 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"3557_CR50","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41375-020-0977-8","volume":"34","author":"O Parting","year":"2020","unstructured":"Parting, O. et al. Therapeutic inhibition of Fc\u03b3RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia. 34 (10), 2635\u20132647 (2020).","journal-title":"Leukemia"},{"key":"3557_CR51","doi-asserted-by":"crossref","unstructured":"Brauneck, F. et al. TIGIT Blockade repolarizes AML-associated TIGIT\u2009+\u2009M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. J. Immunother. Cancer 10(12). (2022).","DOI":"10.1136\/jitc-2022-004794"},{"key":"3557_CR52","doi-asserted-by":"crossref","unstructured":"Weinh\u00e4user, I. et al. M2-polarized macrophages control LSC fate by enhancing stemness, homing, immune evasion and metabolic reprogramming. BioRxiv. 2022:2022.05. 06.489506.","DOI":"10.1101\/2022.05.06.489506"},{"issue":"68","key":"3557_CR53","doi-asserted-by":"publisher","first-page":"112685","DOI":"10.18632\/oncotarget.22340","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 8 (68), 112685 (2017).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03557-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:37:27Z","timestamp":1757259447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03557-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26123"}}